SGLT2 inhibitors have emerged as a promising new class of glucose-lowering drugs for managing type 2 diabetes (T2DM), they increase urinary glucose excretion, thereby reducing hyperglycaemia [14]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.